Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations
Monia Marchetti, Alessandro Maria Vannucchi, Martin Griesshammer, Claire Harrison, Steffen Koschmieder, Heinz Gisslinger, Alberto Álvarez-Larrán, Valerio De Stefano, Paola Guglielmelli, Francesca Palandri, Francesco Passamonti, Giovanni Barosi, Richard T Silver, Rüdiger Hehlmann, Jean-Jacques Kiladjian, Tiziano Barbui
Topics & Concepts
MedicinePolycythaemiaThrombocytosisLeukocytosisRuxolitinibClinical trialInternal medicineIntensive care medicineHydroxycarbamideDaclizumabRandomized controlled trialSurgeryMyelodysplastic syndromesPolycythemia veraPediatricsPhlebotomyGemtuzumab ozogamicinQuality of life (healthcare)DiseaseAlpha interferonOff-label useDeferasiroxFibrinolytic agentHematologyMyeloproliferative Neoplasms: Diagnosis and TreatmentMultiple Myeloma Research and TreatmentsAmyloidosis: Diagnosis, Treatment, Outcomes